Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
3.51 +0.15 (+4.46%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 3.53 +0.02 (+0.57%) 19:50 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.25
Day High
3.64
Open 3.32
Previous Close 3.36 3.36
Volume 14,760,399 14,760,399
Avg Vol 10,164,305 10,164,305
Stochastic %K 78.51% 78.51%
Weighted Alpha -70.62 -70.62
5-Day Change +0.45 (+14.71%) +0.45 (+14.71%)
52-Week Range 2.70 - 14.23 2.70 - 14.23
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 983,631
  • Shares Outstanding, K 327,877
  • Annual Sales, $ 164,070 K
  • Annual Income, $ -372,180 K
  • EBIT $ -395 M
  • EBITDA $ -362 M
  • 60-Month Beta 1.05
  • Price/Sales 7.01
  • Price/Cash Flow N/A
  • Price/Book 1.44

Options Overview Details

View History
  • Implied Volatility 362.39% ( +153.41%)
  • Historical Volatility 83.00%
  • IV Percentile 96%
  • IV Rank 47.92%
  • IV High 715.60% on 04/10/25
  • IV Low 37.36% on 08/15/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 5,169
  • Volume Avg (30-Day) 4,227
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 147,505
  • Open Int (30-Day) 140,604

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 5
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +40.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +30.00%
on 04/07/25
Period Open: 3.48
3.66 -4.10%
on 03/27/25
+0.03 (+0.86%)
since 03/25/25
3-Month
2.70 +30.00%
on 04/07/25
Period Open: 6.25
6.50 -46.00%
on 01/27/25
-2.74 (-43.84%)
since 01/24/25
52-Week
2.70 +30.00%
on 04/07/25
Period Open: 11.54
14.23 -75.33%
on 05/06/24
-8.03 (-69.58%)
since 04/25/24

Most Recent Stories

More News
Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

IOVA : 3.51 (+4.46%)
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.

Iovance Biotherapeutics (NASDAQ: IOVA) is a stock that many investors think has a lot of upside. A year ago, regulators approved its cellular therapy, Amtagvi, to treat unresectable (inoperable) or metastatic...

IOVA : 3.51 (+4.46%)
This Biotech Stock Could Be the Best Investment of the Decade

There's an incredible growth story hiding in plain sight for investors who can look to the future.

IOVA : 3.51 (+4.46%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA : 3.51 (+4.46%)
Is Iovance Biotherapeutics a Millionaire-Maker?

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money. So does investing in most biotech stocks. But...

IOVA : 3.51 (+4.46%)
GILD : 103.17 (-2.81%)
Traws Pharma Announces Management Updates

TRAW : 1.5500 (+1.31%)
IOVA : 3.51 (+4.46%)
IKNA : 1.1900 (-1.65%)
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Though the company reached a significant milestone last year -- with regulatory approval...

IOVA : 3.51 (+4.46%)
3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not

The time to buy quality prospects is when the rest of the market is ignoring their value.

IOVA : 3.51 (+4.46%)
PEP : 133.38 (-1.43%)
SIRI : 21.67 (+1.45%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

IOVA : 3.51 (+4.46%)

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 4.07
2nd Resistance Point 3.86
1st Resistance Point 3.68
Last Price 3.51
1st Support Level 3.29
2nd Support Level 3.08
3rd Support Level 2.90

See More

52-Week High 14.23
Fibonacci 61.8% 9.83
Fibonacci 50% 8.47
Fibonacci 38.2% 7.10
Last Price 3.51
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective